28 results
Thumbnail

D1.50 - Allergic Bronchopulmonary Aspergillosis in a Tertiary Allergy Center: Clinical Characteristics, Radiologic Subtypes, and Biologic Use

Thumbnail

D1.54 - Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry

Thumbnail

D1.46 - Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice

Thumbnail

D1.47 - Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification

Thumbnail

D1.48 - Early-Onset Multiorgan Allergic Phenotype with Transformation into Controlled Asthma in a 2-Year-Old Child: The Role of Molecular Diagnostics (ALEX²) in Risk Stratification

Thumbnail

D1.49 - Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness

Thumbnail

D1.51 - Evaluation of the Correlation Between Skin Prick Test, Specific Immunoglobulin E Levels and Clinical Findings in Children with Cat Allergen Sensitization

Thumbnail

D1.52 - The Borg Fallacy in Olympic Athletes: Symptom Perception Fails to Identify Airway Hyperresponsiveness

Thumbnail

D1.55 - Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis

Thumbnail

D1.57 - New allergens registered in the WHO/IUIS Allergen Database in 2025: new and old foes

Thumbnail

D1.58 - “Evaluation of Chronic Cough in Patients with Allergic Disease, GERD, and Chronic Rhinosinusitis”

Thumbnail

D1.60 - Clinical Characteristics of Children with Patch Test–Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to